Correction: CTE-type tau filaments in Alzheimer’s disease with co-morbid LATE-NC

• by Jaimin K. Rana, Emile S. Pinarbasi, Martin G. Fernandez, Vikas Navratna, Kyle S. Conway, Andrew P. Lieberman, Sami J. Barmada, Shyamal Mosalaganti

• August 20, 2026

Phoenix Children’s Joins First Controlled Clinical Trial of Genetic Therapy for Dravet Syndrome

The first controlled phase 3 trial of a genetic therapy for Dravet syndrome is now underway – with Phoenix Children's as one of 28 sites nationwide.

• by

• August 13, 2026

• 4 min

FDA approves tau PET imaging agent

The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.

• by Kathryn Wighton

• August 14, 2026

• 2 min

International Consensus on the Evaluation and Management of : Results From a Modified Delphi Survey

Hypothalamic hamartomas (HH) are rare developmental brain lesions frequently associated with medically refractory epilepsy and complex neurobehavioral, cognitive and endocrine comorbidities.

• by

• August 14, 2026

• 2 min